In addition, some patients actually manifest psoriasiform eruption with IL-23/IL-17A overexpression during dupilumab therapy, suggesting that IL-23/IL-17A axis is potentially active and meaningful in these particular AD patients [149]. Here, IL17A is linked to Alzheimer disease.